Fluorobiphenyl Carboxylic Acid Derivatives Stabilizing TTR Tetramers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for transthyretin (TTR) amyloidosis, such as gene therapy, are invasive and have limited effectiveness, and there is a need for more effective small molecule therapeutic agents that can stabilize the native TTR tetrameric structure to prevent misassembly and fibrillogenesis without causing significant side effects.
Innovation Solution
The use of 1-(2-fluorobiphenyl-4-yl)-alkyl carboxylic acid derivatives, specifically compounds of general formula (I) with methyl or cyclopropyl groups and chlorine substituents, which bind with high affinity to TTR, stabilizing the tetrameric state and inhibiting its dissociation into monomers, thereby preventing amyloid fibril formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If gene therapy is used to treat TTR amyloidosis, then treatment effectiveness is improved, but invasiveness and complexity increase
Solution Approach 1:
The patent replaces the mechanical/surgical approach of gene therapy with a chemical/small molecule approach. The small molecule compounds bind to TTR and stabilize its native tetrameric structure, preventing amyloid fibril formation without requiring surgical intervention or genetic modification. This substitutes a complex medical procedure with a simpler pharmacological treatment.
2Reliability
If NSAIDs are used to stabilize TTR tetrameric structure, then fibrillogenesis inhibition is improved, but gastrointestinal side effects increase
Solution Approach 1:
The patent modifies the chemical structure of NSAID-like compounds by introducing specific substituents (R1, R2, R3 groups) to create a more selective binder. The compounds maintain the ability to stabilize TTR tetramer structure while reducing non-specific interactions with cyclooxygenase-2 and other off-target proteins, thereby minimizing gastrointestinal side effects while preserving fibrillogenesis inhibition.
Solution Approach 2:
The patent systematically varies chemical parameters (substituents R1, R2, R3) to optimize the balance between TTR binding affinity and selectivity. By adjusting these molecular parameters, the compounds achieve high stabilizing effect on TTR while reducing off-target binding that causes side effects, creating an improved therapeutic profile compared to conventional NSAIDs.
3Force
If polyphenols are used to bind TTR, then binding affinity is improved, but selectivity and bioavailability decrease
Solution Approach 1:
The patent introduces specific local structural features (halogen substituents at defined positions R1, R2, R3) that create a more selective interaction profile. These localized modifications enhance binding to the TTR thyroxine binding site while reducing non-specific binding to other proteins, thereby improving both selectivity and effective bioavailability compared to generic polyphenols.
Data Source
AI summary
The invention relates to the use of derivatives of 1-(2-fluorobiphenyl-4- yl)-alkyl carboxylic acid as agents capable of stabilising the tetrameric native state of transthyretin for the prophylaxis and treatment of amyloidosis.